Led · Equity · Feb 2025

BEKhealth, based in Research Triangle Park, NC, provides an AI-powered chart abstraction and patient-matching platform that extracts structured and unstructured data from electronic medical records (EMRs). The technology integrates EHR data to optimize population feasibility and rapidly identify clinically qualified participants for clinical research. Its platform supports organizations conducting clinical trials, observational research, and real-world evidence generation by improving protocol design and participant identification. The company announced customer growth in 2024 and now counts clients such as Avacare Clinical Research Network, Biopharma Informatics, Chemidox, Elixia Health, Javara, Om Research and others. BEKhealth raised $4M in funding and intends to use the proceeds to continue expanding its customer base and product offering. The company highlights its focus on expanding commercial adoption and enhancing its AI-driven capabilities to better serve research sponsors and sites. BEKHealth offers an AI-powered clinical research software platform that ingests and processes both structured and unstructured EMR data to drive feasibility assessments, site selection, precision patient matching, and care coordination. Its machine learning models combine more than 400 unique medical libraries and 70,000 research protocols with an interoperable clinical data model to power automated, daily identification of protocol-eligible patients. The platform is positioned to accelerate patient enrollment, cut timelines, and improve outcomes for sites and CROs while addressing cumbersome workflows and data access challenges. BEKHealth says its tools are increasingly in demand amid a more virtual healthcare environment and growing use of analytics in clinical research. The company is privately held, venture-backed, and based in Connecticut, and plans to use new funding to grow its team and expand availability and adoption of its platform.

Participated · Series A · Oct 2023

Korio offers a randomization and trial supply management (RTSM) platform designed to improve clinical trial quality, speed, and reliability. The platform enables users to adapt to protocol changes, surface audit trails and cross-portfolio data, and flag integration disruptions. When customers need guidance, Korio provides access to knowledgeable and responsive RTSM experts. Led by CEO Ryan Keane and based in Doylestown, PA, the company emphasizes expert client services and support. Korio intends to use the Series A proceeds to accelerate global expansion with a focus on its client services and support team. Financial terms of the round were not disclosed; the round was led by BIP Ventures with participation from existing investors Excelerate Health Ventures, Boston Millennia Partners, and other strategic investors. Korio offers a clinical trial software platform focused on Randomization & Trial Supply Management (RTSM) that streamlines processes and delivers predictable outcomes within shorter timeframes. The platform integrates insights and expertise from industry subject‑matter experts to challenge complex, manual workflows common among RTSM providers. Led by CEO Ryan Keane, the company emphasizes a technology‑first approach to replace manual processes. Korio intends to use its recent funding to support expansion and to bolster its team. The company said the capital will help it respond to increasing demand from life sciences and clinical research organizations. The articles do not disclose additional operating metrics or past financing details.

Participated · Series A · Aug 2022

Atropos Health builds GENEVA OS™, an operating system that converts real-world clinical data into high-quality, personalized real-world evidence and offers vertical user experiences such as ChatRWD™. ChatRWD, launched in beta in Q4 2023, is a chat-based AI co-pilot that the company says cuts production time for publication-grade evidence from months to minutes while aiming to minimize hallucination risk. The platform has been adopted by healthcare institutions, data platforms, research institutions, and life sciences companies. The company positions its products as a trusted quality layer between healthcare data and clinical/research evidence, and aims to democratize access to real-world evidence to improve decision making and patient outcomes. With this funding, Atropos plans to expand its focus on value-based care, deepen vertical integrations (including oncology and specialty care), and scale automation and full launch of ChatRWD. Atropos Health develops GENEVA OS, a Generative Evidence Acceleration Operating System that powers the Atropos Evidence Network and analyzes de-identified medical records. The company says the network includes more than 160 million patients’ de-identified medical data and its new ChatRWD application delivers answers in minutes via natural-language queries and a chat interface. Atropos recently partnered with Google Cloud to optimize GENEVA OS for Google’s healthcare data tools, enabling datasets hosted in Google Cloud to join the Evidence Network seamlessly. The integration is intended to let health systems and pharmaceutical companies generate near-instant insights for use cases such as optimizing formularies, reducing length of stay, accelerating research, and supporting shared decision-making. Atropos emphasizes rigorous data privacy and security measures within Google Cloud’s infrastructure. Financially, the company said it raised an undisclosed strategic financing from Presidio Ventures, Samsung Next, and others to support expansion and its mission to close evidence gaps in medicine worldwide. Atropos Health is a Palo Alto–based developer of a physician consultation service that delivers research-grade real-world evidence at the point of care. The company uses millions of anonymized patient records to help providers answer clinical questions that have fallen through the cracks of the evidence-based literature. Led by newly appointed CEO Brigham Hyde, PhD, Atropos retains President Neil Sanghavi and CMO Dr. Saurabh Gombar, while co-founder Nigam Shah remains on the board. The company will use the $14M Series A to expand its commercial team, build on recent market traction, and continue development of its oncology product. The financing supports continued product development and commercial expansion.

Participated · Series A · May 2022

KAID Health builds the Whole Chart Analysis™ platform, an NLP-centric solution that integrates structured EMR data and insights distilled from clinical notes using the latest language models. The product collects comprehensive patient data to improve coding accuracy, capture, quality reporting, and care management while reducing clinician and staff burden. KAID's technology is used across leading providers, health systems, academic medical centers, and payers and is proven in commercial settings and peer-reviewed literature. Today it improves Medicare Advantage coding accuracy and completeness for large provider groups across the U.S. and also streamlines chart review for prior authorization, clinical trial enrollment, and preoperative risk identification. With new funding, KAID plans to bolster its market footprint among providers and payer partners and to enable significant service expansion. KAID Health’s core product is a natural language processing–centric Whole Chart Analysis platform that extracts structured and text data from electronic medical records and pushes identified care and coding gaps into provider workflows. The platform can financially reward providers for timely completion of assigned tasks and is used across use cases including Medicare Advantage coding accuracy, automated quality metric reporting, prior authorization chart review, and pre-operative risk identification. KAID sells to and works with providers, health systems, academic medical centers, payers, and Accountable Care Organizations. The company reports that its solution has delivered over 10x return on investment for customers and is built in conjunction with leading provider organizations. With the new financing, KAID plans to bolster its market footprint among providers while furthering collaboration between providers and health plans and ACO partners. The company is based in Boston, MA.

Participated · Equity · Dec 2021

Health Data Vision, Inc. delivers a cloud-based platform that streamlines the collection, analysis, and review of medical records for U.S. health plans and providers. Its software supports HEDIS Hybrid, Medicare RAPS, RADV, and ACO quality review initiatives through flexible workflows, automation, audit features, and real-time analytics. The company plans to enhance the platform with self-provisioning for clients and partners, expanded electronic records retrieval (developed with MEA), deeper real-time analytics on clinical and process metadata, and new mobile/tablet interfaces for executive, management, and clinical users. Building a broad partner community and scaling operations are key strategic goals. The recent capital infusion will finance these product expansions, additional services, and growth in sales and partner channels. No operating metrics such as revenue or user counts were disclosed in the article.